Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | PREP | P48147 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495907 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL13596273 | 0.88 | CHRM2 (0.45) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL10139209 | 0.88 | CHRM2 (0.45) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL13632125 | 0.87 | CHRNB2 (0.59) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL10139726 | 0.85 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL10139215 | 0.85 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL10139208 | 0.83 | CHRNB2 (0.41) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL16777487 | 0.83 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1722273 | 0.82 | CHRM2 (0.41) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL15085021 | 0.82 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606052-B1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9284322-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284322-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2015-06-04 | — | — | US | disclosed |
| US-8981102-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981102-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981102-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2606052-A1 | NICOTINIC RECEPTOR COMPOUNDS | Research Triangle Institute (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024615-A1 | NICOTINIC RECEPTOR COMPOUNDS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024615-A1 | NICOTINIC RECEPTOR COMPOUNDS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-23 | — | — | WO | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRM2 47/4885CHRM1 25/4885CHRM3 41/4885 |
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | CHRNG, CHRNA7, CHRNA2 | CHRM2 19/4885CHRM1 23/4885CHRM3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.